Two and a half years into his tenure as Teva’s CEO, Richard Francis is breaking down the strategy that’s powered the company ...

A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...

After over a decade spent building Incyte up into a competitive commercial drugmaker, the company’s longtime CEO Hervé ...

The CDC’s Advisory Committee on Immunization Practices (ACIP) has blessed Merck’s new respiratory syncytial virus (RSV) shot ...

For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...

Robert F. Kennedy Jr.’s revamped Advisory Committee on Immunization Practices has struck its first blow against established ...

A Fierce Pharma Marketing review of the LinkedIn and Instagram pages of the 20 largest pharmas found that, as of Thursday, ...

A little less than a year after topping up its medical countermeasure contracts with Emergent BioSolutions, the federal ...

U.S. multinational company Abbott entered a partnership with Abu Dhabi's Department of Health to manufacture medicines in the ...